The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue The Journal of clinical investigation Année : 2021

The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model

Shaoxia Yu
  • Fonction : Auteur
Lenny Dang
Tomas Ganz
Carlo Brugnara

Résumé

Anemia in β-thalassemia is related to ineffective erythropoiesis and reduced red cell survival. Excess free heme and accumulation of unpaired α-globin chains impose substantial oxidative stress on β-thalassemic erythroblasts and erythrocytes, impacting cell metabolism. We hypothesized that increased pyruvate kinase activity induced by mitapivat (AG-348) in the Hbb th3/+ mouse model for β-thalassemia would reduce chronic hemolysis and ineffective erythropoiesis through stimulation of red cell glycolytic metabolism. Oral mitapivat administration ameliorated ineffective erythropoiesis and anemia in Hbb th3/+ mice. Increased ATP, reduced reactive oxygen species production, and reduced markers of mitochondrial dysfunction associated with improved mitochondrial clearance suggested enhanced metabolism following mitapivat administration in β-thalassemia. The amelioration of responsiveness to erythropoietin resulted in reduced soluble erythroferrone, increased liver Hamp expression, and diminished liver iron overload. Mitapivat reduced duodenal Dmt1 expression potentially by activating the pyruvate kinase M2-HIF2α axis, representing a mechanism additional to Hamp in controlling iron absorption and preventing β-thalassemia-related liver iron overload. In ex vivo studies on erythroid precursors from patients with β-thalassemia, mitapivat enhanced erythropoiesis, promoted erythroid maturation, and decreased apoptosis. Overall, pyruvate kinase activation as a treatment modality for β-thalassemia in preclinical model systems had multiple beneficial effects in the erythropoietic compartment and beyond, providing a strong scientific basis for further clinical trials.

Domaines

Autre [q-bio.OT]
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée

Dates et versions

inserm-03868319 , version 1 (23-11-2022)

Identifiants

Citer

Alessandro Matte, Enrica Federti, Charles Kung, Penelope A Kosinski, Rohini Narayanaswamy, et al.. The pyruvate kinase activator mitapivat reduces hemolysis and improves anemia in a β-thalassemia mouse model. The Journal of clinical investigation, 2021, 131 (10), pp.e144206. ⟨10.1172/jci144206⟩. ⟨inserm-03868319⟩
7 Consultations
4 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More